Overview

Selinexor, also known by the development code KPT-330 and marketed under names such as Sailidx and Xpovio, is an orally administered small-molecule medicine built around a distinctive principle: instead of blocking a kinase, it interferes with the cellular machinery that moves proteins out of the nucleus. This class of agents is referred to as Selective Inhibitors of Nuclear Export, or SINE compounds. In routine B2B pharmaceutical sourcing, the product is commonly offered in a 20 mg per tablet strength packaged as 16 tablets per box, which matches the presentation used in its approved oncology indications.

How Selinexor Targets Exportin 1

The molecular target of selinexor is exportin 1, also called XPO1 or CRM1. Under normal conditions, XPO1 acts as a shuttle that carries cargo proteins - including tumor suppressor and growth-regulatory proteins - from the nucleus to the cytoplasm. Selinexor binds to a specific cysteine residue on XPO1 and inhibits this export process. As a result, proteins such as p53, p21, FOXO family members, and BRCA1/2 remain inside the nucleus rather than being transported out.

This nuclear retention is mechanistically important because many of these retained proteins carry out tumor-suppressing functions: they can trigger cell-cycle arrest, promote DNA-repair checks, and ultimately push damaged cancer cells toward apoptosis. By restoring the accumulation of these endogenous regulatory proteins, the agent is designed to selectively stress cancer cells while leaving many normal cells comparatively less affected.

XPO1 as a Therapeutic Target

From a pharmacology standpoint, XPO1 was an unusual target when selinexor became the first-in-class SINE compound to reach approval. Rather than competing at an ATP-binding site like many kinase inhibitors, selinexor acts on a nuclear transport protein, opening a separate route for intervention in hematologic malignancies. Per FDA labeling, selinexor is approved in combination with dexamethasone for heavily pretreated adult multiple myeloma, and as a single agent under accelerated approval for certain adults with relapsed or refractory diffuse large B-cell lymphoma after prior lines of therapy.

For procurement teams and formulary reviewers, the mechanism also informs handling: selinexor is an oral tablet taken on a defined weekly-style schedule, which simplifies logistics compared with infusional therapies, though it still requires cold-chain awareness and documented storage. Understanding the XPO1 mechanism helps buyers and clinicians distinguish this molecule from conventional targeted therapies and appreciate why it is positioned as a later-line or combination backbone rather than a first exposure agent.

FAQ

Q: What exactly does selinexor inhibit inside the cell? A: Selinexor selectively inhibits exportin 1 (XPO1/CRM1), the nuclear export protein responsible for shuttling tumor suppressor proteins out of the nucleus. Inhibition causes those proteins to accumulate in the nucleus.

Q: Is selinexor the same molecule as Xpovio and Sailidx? A: Yes. Selinexor is the international nonproprietary name; Xpovio and Sailidx are brand presentations of the same active substance, supplied in strengths such as 20 mg tablets.

Q: Why is the 20 mg x 16 tablet pack relevant for B2B buyers? A: The 16-tablet box at 20 mg per tablet reflects the registered presentation used in its oncology indications, which matters for batch traceability, import documentation, and matching the labeled dosing schedule.

Q: Does the XPO1 mechanism mean selinexor works like a standard targeted therapy? A: Not exactly. Most targeted agents block kinase signaling, whereas selinexor blocks nuclear protein export, making it a mechanistically distinct option often used in combination or later-line settings.